Climb Bio is a clinical-stage biotechnology company developing disease-modifying therapies for immune-mediated conditions. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody being studied in B-cell–driven diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus; a second program targets APRIL for IgA nephropathy. The company has no commercial products and focuses on advancing candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -8.7 | — |
| Q3 2025 | 0 | — | -12.9 | — |
| Q4 2025 | 0 | — | -17.5 | — |
| Q1 2026 | 0 | — | -13.7 | — |
| Q2 2026 | 0 | — | -13.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Phathom Pharmaceuticals, Inc. (PHAT), Civista Bancshares, Inc. (CIVB), HIVE Digital Technologies Ltd. (HIVE), Bank7 Corp. (BSVN), Hallador Energy Company (HNRG), Ballard Power Systems Inc. (BLDP)